For the current quarter, analysts are expecting Citigroup Inc. (NYSE:C) to report EPS of $1.26. This consensus estimate is provided by Zacks Research. After the period that ended on 2017-03-31, Citigroup Inc. (NYSE:C) reported an EPS actual of $1.36. The difference between the actual and estimate resulted in a surprise factor of 9.68%. The company is expected to release their next earnings report on or around 2017-07-14. Interested parties will be watching to see how company results compare to what the Street was projecting for the fiscal period.
Shares of Citigroup Inc. (NYSE:C) have a current ABR or average broker rating of 1.82. This consensus recommendation is also provided by Zacks Research. The recommendation falls on a scale between 1 and 5. A broker rating of 1 would translate into a Strong Buy. A rating of 5 would indicate a Strong Sell recommendation. This consensus broker rating may help shed some light on how the sell-side is currently viewing company stock.
Covering analysts often provide target price projections for company shares. The current Zacks consensus target price on shares of Citigroup Inc. (NYSE:C) is $64.5. The top analyst target is $77, and the lowest target is $50 on the stock. Because of the different techniques used to gauge a company target price, estimates may be quite different from one analyst to another.
According to data provided by Zacks Research, Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has a consensus target price of $168.3 on the stock. Out of the polled analysts providing targets, the high is currently $332, while the low is resting at $60. Analyst price targets may vary depending on the individual method used to calculate the estimate.
Turning to earnings, analysts are expecting Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to post a current quarter EPS of $-4.27. This consensus number is compiled by Zacks Research. For the period ending on 2016-12-31, the company reported EPS for the quarter of $-4.84. The resulting surprise factor from the difference between the reported number and the consensus estimate going into earnings was -35.2%. After a company reports earnings, the stock may see increased activity. The next earnings report date is scheduled on or near 2017-05-04.
In terms of analyst ratings, Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has a current ABR of 2.16. This average broker recommendation is given by Zacks using a scale from 1 to 5. According to this scale, a rating of 1 or 2 would indicate a Buy, and a rating of 4 or 5 would signify a Sell recommendation. A 3 would indicate a Hold on the stock.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.